<p>Trevi Therapeutics Inc. has announced the appointment of David Hastings as Chief Financial Officer and principal financial officer, effective January 6, 2026. Under the terms of his offer letter, Hastings will receive an annualized base salary of $522,000 and will be eligible for an annual incentive bonus of up to 40% of his base salary. In addition, upon commencing employment, he will be granted an option to purchase 375,000 shares of the company’s common stock at the closing price on the date of grant. The stock option will vest 25% after one year, with the remainder vesting in equal monthly installments over the following three years. Hastings will also be eligible for separation benefits under the company’s Executive Separation Benefits and Retention Plan. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trevi Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-308769), on December 05, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

TRVI

<p>Trevi Therapeutics Inc. has appointed David Hastings as CFO, effective January 6, 2026. He will receive a $522,000 annual salary, a bonus up to 40% of his salary, and stock options for 375,000 shares. The stock options vest over four years. Hastings is also eligible for separation benefits under the company's plan.</p>

Trevi Therapeutics Sets $522,000 Salary and Bonus Package for New CFO